Your browser doesn't support javascript.
loading
Evidence favouring the efficacy of convalescent plasma for COVID-19 therapy
Stephen A Klassen; Jonathon Senefeld; Patrick W Johnson; Rickey E. Carter; Chad C. Wiggins; Shmuel Shoham; Brenda J. Grossman; Jeffrey P. Henderson; James M. Musser; Eric Salazar; William R. Hartman; Nicole M. Bouvier; Sean T.H. Liu; Liise-anne Pirofski; Sarah E. Baker; Noud Van Helmond; R. Scott Wright; DeLisa Fairweather; Katelyn A. Bruno; Nigel S. Paneth; Arturo Casadevall; Michael J Joyner.
Afiliación
  • Stephen A Klassen; Mayo Clinic
  • Jonathon Senefeld; Mayo Clinic
  • Patrick W Johnson; Mayo Clinic
  • Rickey E. Carter; Mayo Clinic
  • Chad C. Wiggins; Mayo Clinic
  • Shmuel Shoham; Johns Hopkins University
  • Brenda J. Grossman; Washington University School of Medicine in St. Louis
  • Jeffrey P. Henderson; Washington University School of Medicine in St. Louis
  • James M. Musser; Houston Methodist Hospital
  • Eric Salazar; Houston Methodist Hospital
  • William R. Hartman; University of Wisconsin-Madison
  • Nicole M. Bouvier; Icahn School of Medicine at Mount Sinai
  • Sean T.H. Liu; Icahn School of Medicine at Mount Sinai
  • Liise-anne Pirofski; Albert Einstein College of Medicine
  • Sarah E. Baker; Mayo Clinic
  • Noud Van Helmond; Cooper Medical School of Rowan University
  • R. Scott Wright; Mayo Clinic
  • DeLisa Fairweather; Mayo Clinic
  • Katelyn A. Bruno; Mayo Clinic
  • Nigel S. Paneth; Michigan State University
  • Arturo Casadevall; Johns Hopkins School of Public Health
  • Michael J Joyner; Mayo Clinic
Preprint en En | PREPRINT-MEDRXIV | ID: ppmedrxiv-20162917
ABSTRACT
To determine the effect of COVID-19 convalescent plasma on mortality, we aggregated patient outcome data from randomized clinical trials, matched control, case series, and case report studies. Fixed-effects analyses demonstrated that hospitalized COVID-19 patients transfused with convalescent plasma exhibited a ~57% reduction in mortality rate (10%) compared to matched-patients receiving standard treatments (22%; OR 0.43, P < 0.001). These data provide evidence favouring the efficacy of human convalescent plasma as a therapeutic agent in hospitalized COVID-19 patients.
Licencia
cc_no
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-MEDRXIV Tipo de estudio: Experimental_studies / Observational_studies / Prognostic_studies / Rct Idioma: En Año: 2020 Tipo del documento: Preprint
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-MEDRXIV Tipo de estudio: Experimental_studies / Observational_studies / Prognostic_studies / Rct Idioma: En Año: 2020 Tipo del documento: Preprint